The Salk Institute for Biological Studies

The Scripps Research Institute

Sanford Burnham Prebys Medical Discovery Institute

Sanford-burnham Medical Research Institute

John M Marlett

Nicholas David Peter Cosford

Mitchell Dennis Vamos

John A T Young

Marc Siladi

Sumit K Chanda

Godfrey Jonah Anderson Rainey

Mark J Yeager

John Young

Peter Teriete

Heather M Scobie

Anette Schneemann

Diane Thomas

Vijay Reddy

Darly Joseph Manayani

Kelly Dryden

Marianne Manchester

Arturo Diaz

Lars Pache

John At Young

John AT Young

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.

Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.

Antitoxin and vaccine platform based on nodavirus VLPS

Antitoxin and vaccine platform based on nodavirus VLPs

Growing community of inventors

San Diego, CA, United States of America

John M Marlett